Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.
Several other equities research analysts also recently weighed in on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, January 10th. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, February 1st. They set a “buy” rating and a $66.00 target price for the company. B. Riley reiterated a “buy” rating and set a $54.00 target price on shares of Supernus Pharmaceuticals in a research note on Thursday, January 18th. Finally, Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Monday, December 4th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Supernus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $51.36.
Shares of SUPN stock opened at $45.35 on Wednesday. Supernus Pharmaceuticals has a 12 month low of $27.80 and a 12 month high of $50.04. The firm has a market cap of $2,303.71, a PE ratio of 42.78 and a beta of 1.07.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The business had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. research analysts expect that Supernus Pharmaceuticals will post 1.87 earnings per share for the current fiscal year.
In related news, VP Padmanabh P. Bhatt sold 20,000 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.04, for a total transaction of $960,800.00. Following the completion of the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at $1,561,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Victor Vaughn sold 55,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. Insiders have sold 165,750 shares of company stock valued at $7,133,973 over the last three months. 6.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Thomson Horstmann & Bryant Inc. increased its holdings in Supernus Pharmaceuticals by 8.8% in the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 28,556 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after buying an additional 2,305 shares in the last quarter. Braun Stacey Associates Inc. purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $440,000. Neuberger Berman Group LLC purchased a new position in Supernus Pharmaceuticals in the third quarter valued at about $660,000. BlackRock Inc. increased its holdings in Supernus Pharmaceuticals by 1.8% in the fourth quarter. BlackRock Inc. now owns 6,902,230 shares of the specialty pharmaceutical company’s stock valued at $275,054,000 after buying an additional 120,394 shares in the last quarter. Finally, First Trust Advisors LP purchased a new position in Supernus Pharmaceuticals in the third quarter valued at about $2,255,000. 96.21% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals (SUPN) Upgraded to Strong-Buy by BidaskClub” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/03/21/supernus-pharmaceuticals-supn-upgraded-to-strong-buy-by-bidaskclub.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.